DK1685840T3 - Anvendelse af tetrahydrofolater til modulering af homocysteinniveauet - Google Patents

Anvendelse af tetrahydrofolater til modulering af homocysteinniveauet

Info

Publication number
DK1685840T3
DK1685840T3 DK06006085.2T DK06006085T DK1685840T3 DK 1685840 T3 DK1685840 T3 DK 1685840T3 DK 06006085 T DK06006085 T DK 06006085T DK 1685840 T3 DK1685840 T3 DK 1685840T3
Authority
DK
Denmark
Prior art keywords
tetrahydrofolates
homocysteine
methylene tetrahydrofolate
notably
deficiencies
Prior art date
Application number
DK06006085.2T
Other languages
English (en)
Inventor
Hans Rudolf Mueller
Martin Ulmann
Rudolf Moser
Original Assignee
Merck & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4210897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1685840(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Cie filed Critical Merck & Cie
Application granted granted Critical
Publication of DK1685840T3 publication Critical patent/DK1685840T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicinal Preparation (AREA)
DK06006085.2T 1997-06-13 1998-06-05 Anvendelse af tetrahydrofolater til modulering af homocysteinniveauet DK1685840T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH01456/97A CH693255A5 (de) 1997-06-13 1997-06-13 Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
EP98110302A EP0898965B9 (de) 1997-06-13 1998-06-05 Verwendung von 5-methyl-(6S)-tetrahydrofolsäure zur Vorbeugung von Neuralrohrdefekten

Publications (1)

Publication Number Publication Date
DK1685840T3 true DK1685840T3 (da) 2012-04-10

Family

ID=4210897

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06006085.2T DK1685840T3 (da) 1997-06-13 1998-06-05 Anvendelse af tetrahydrofolater til modulering af homocysteinniveauet
DK98110302T DK0898965T3 (da) 1997-06-13 1998-06-05 Anvendelse af 5-methyl-(6S)-tetrahydrofolsyre til forebyggelse af neuralrörsdefekter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98110302T DK0898965T3 (da) 1997-06-13 1998-06-05 Anvendelse af 5-methyl-(6S)-tetrahydrofolsyre til forebyggelse af neuralrörsdefekter

Country Status (15)

Country Link
US (1) US6011040A (da)
EP (2) EP0898965B9 (da)
JP (1) JPH11116482A (da)
CN (1) CN102151271A (da)
AT (2) ATE538793T1 (da)
AU (1) AU739544B2 (da)
CA (1) CA2240571C (da)
CH (1) CH693255A5 (da)
DE (1) DE59813465D1 (da)
DK (2) DK1685840T3 (da)
ES (2) ES2376472T3 (da)
PT (2) PT898965E (da)
RU (1) RU2226099C2 (da)
TW (1) TW474812B (da)
ZA (1) ZA985129B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0877563T3 (da) 1996-01-31 2004-07-26 Univ South Alabama Levnedsmiddel- og vitaminpræparater, der indeholder den naturlige isomer af reducerede folater
WO2000007566A1 (en) * 1998-08-03 2000-02-17 Epigenesis Pharmaceuticals, Inc. A new analgesic, anti-inflammatory and wound healing agent
DE10062401A1 (de) * 2000-12-14 2002-06-20 Beiersdorf Ag Verwendung von Folsäure und/oder deren Derivaten zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe von Schäden an der hauteigenen DNA und/oder zur Reparatur bereits eingetretener Schäden an der hauteigenen DNA
WO2002083151A2 (en) * 2000-12-14 2002-10-24 Tufts University Compositions and methods for treating an arthritic condition
FR2828076B1 (fr) * 2001-07-31 2003-11-07 Olivier Laroche Banquette pour musicien
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
SE0303526D0 (sv) * 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
EP2436379A1 (en) 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
AU2005313940A1 (en) * 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
US7687473B2 (en) * 2005-01-07 2010-03-30 Health Research, Inc. 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism
WO2006119589A2 (en) * 2005-05-11 2006-11-16 Ramaekers, Vincent Prevention and therapy of cerebral folate deficiency
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US20060293295A1 (en) * 2005-05-13 2006-12-28 Kai Strothmann Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
DE102005023301B4 (de) * 2005-05-13 2012-05-31 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
AU2012227235B2 (en) * 2005-05-13 2015-06-11 Bayer Intellectual Property Gmbh Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate
EP2037935A1 (de) * 2006-07-06 2009-03-25 Bayer Schering Pharma AG Pharmazeutische zubereitung zur kontrazeption und zur verminderung des risikos angeborener fehlbildungen
US8617597B2 (en) * 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US20080064702A1 (en) * 2006-09-08 2008-03-13 Charalambos Antoniades Use of folates for the prevention and treatment of vascular diseases
JP2010523708A (ja) 2007-04-11 2010-07-15 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンを投与する方法、関連する組成物および測定方法
EP2027855A1 (de) * 2007-08-24 2009-02-25 Bayer Schering Pharma AG Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität
US20090060997A1 (en) * 2007-08-27 2009-03-05 Christian Seitz Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and (6s)-5-methyltetrahydrofolate
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
US20110097405A1 (en) * 2008-02-13 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
WO2009158430A1 (en) 2008-06-25 2009-12-30 Iskandar Bermans S (6s)-5-methyltetrahydrofolic acid for therapy of tissue injury
IL256966B2 (en) 2009-07-10 2023-12-01 O Scott Linzy Iii Methods and compositions for the treatment of diseases related to the thyroid gland, with a reduced amount of folates
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
CA2825428C (en) 2010-02-12 2022-06-14 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US20160053281A1 (en) 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
WO2016185413A1 (en) 2015-05-20 2016-11-24 Nestec S.A. Modified release formulations
US11110113B2 (en) 2016-11-03 2021-09-07 Gentelon, Inc. Compositions and methods for treating depression
EP3609894A1 (en) * 2017-03-31 2020-02-19 Merck Patent GmbH Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid
CA3058252A1 (en) * 2017-03-31 2018-10-04 Merck Patent Gmbh Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1350160A (en) * 1971-06-29 1974-04-18 Foremost Mckesson Pharmaceutical compositions
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
DK0432441T3 (da) * 1989-12-11 1996-07-29 American Cyanamid Co Fremgangsmåde til fremstilling af optisk rene diastereoisomere af tetrahydrofolatforbindelser
AU7953291A (en) * 1990-05-11 1991-12-10 Goran Carlsson 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
CH682664A5 (en) * 1991-10-15 1993-10-29 Eprova Ag Stable salts of 5,10-methylene tetrahydrofolate.
CH684644A5 (de) * 1992-07-13 1994-11-15 Eprova Ag 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
ZA936723B (en) * 1992-09-14 1995-08-14 Vesta Med Pty Ltd Pharmaceutical preparations for lowering homocysteine levels
CH689831A5 (de) * 1995-11-07 1999-12-15 Eprova Ag Stabile kristalline Tetrahydrofolsaeure-Salze.
DK0877563T3 (da) * 1996-01-31 2004-07-26 Univ South Alabama Levnedsmiddel- og vitaminpræparater, der indeholder den naturlige isomer af reducerede folater
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid

Also Published As

Publication number Publication date
AU7007998A (en) 1998-12-17
EP1685840A3 (de) 2010-06-02
ATE538793T1 (de) 2012-01-15
AU739544B2 (en) 2001-10-18
JPH11116482A (ja) 1999-04-27
EP0898965A3 (de) 2000-11-15
DE59813465D1 (de) 2006-05-18
EP0898965A2 (de) 1999-03-03
ES2376472T3 (es) 2012-03-14
EP0898965B9 (de) 2006-08-09
TW474812B (en) 2002-02-01
DK0898965T3 (da) 2006-07-31
CN102151271A (zh) 2011-08-17
CA2240571C (en) 2006-08-08
RU2226099C2 (ru) 2004-03-27
ATE321555T1 (de) 2006-04-15
ZA985129B (en) 1998-12-14
CA2240571A1 (en) 1998-12-13
EP1685840A2 (de) 2006-08-02
PT898965E (pt) 2006-08-31
PT1685840E (pt) 2012-02-09
US6011040A (en) 2000-01-04
EP1685840B1 (de) 2011-12-28
CH693255A5 (de) 2003-05-15
ES2262202T3 (es) 2006-11-16
EP0898965B1 (de) 2006-03-29

Similar Documents

Publication Publication Date Title
DK1685840T3 (da) Anvendelse af tetrahydrofolater til modulering af homocysteinniveauet
WO1999045949A3 (en) Use of follistatin to modulate gdf-8 and bmp-11
BR9908222A (pt) Composições para regular a aparência da pele
NO961087L (no) K-252a derivater som öker neuorotrofin-indusert aktivitet
WO2004050033A3 (en) Method of treating cancers
ATE353010T1 (de) Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung
WO2003068148A3 (en) Treatment of sleep disorders using sleep target modulators
NO975858L (no) Anvendelse av et ekstrakt av Cimicifuga racemosa
NO975234L (no) Fremgangsmåte for behandling av maniske og bipolare forstyrrelser
DK0706385T3 (da) Anvendelse af isovaleramid som et mildt anxiolytisk og et mildt sedativt middel
ATE237341T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l- carnitin derivate und ginkgo biloba extrakte
WO1998022101A3 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
EP1105145A4 (en) METHOD AND PHARMACEUTICAL COMPOSITION FOR REDUCING THE PLASMATIC CONCENTRATION OF HOMOCYSTEIN
NO20001196L (no) Nootropisk middel
NO984572D0 (no) Anvendelse av 2,5-dihydroksybenzensulfonderivater for fremstilling av legemidler ment for normalisering av den endoteliale funksjon, for behandling av seksuell dysfunksjon og vaskulµre komplikasjoner i diabetes, sÕvel som vaskulµre lidelser av e
ATE286402T1 (de) Verwendung von morinda citrifolia zur behandlung von tinnitus
WO2005021026A3 (en) Methods for treating or ameliorating ghrelin-associated diseases and disorders
WO2001034550A3 (en) 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
IL120521A0 (en) Use of bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders and acute liver disorders
WO2002085341A3 (en) Composition, containing carnitine and huperzin for the preventionor treatment of learning disorders in children suffering from attention deficit/hyperactive disorder
WO2007019378A3 (en) Method of treating neurological disorders
AR027958A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades vasculares, que comprende propionil l-carnitina y coenzima q10
Schaffer et al. Barrett's syndrome presenting as globus hystericus.
AU2427300A (en) Use of extracts from ginkgo biloba leaves for treating sleep disorders
BR0007901A (pt) Método para a preservação ou redução deeventos cardiovasculares associados comintervenção coronária